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K e y  M e s s a g e s 
1. In general, human and swine viruses bind to 
host respiratory tract surface molecules that 
have an α2-6 linkage between sialic acid (Sia) 
and adjacent sugar molecules. Avian viruses 
preferentially bind to host receptors with an α2-3 
linkage. Information on controlling influenza 
virus infection by removing Sia from the host 
surface is limited.
2. Lectin histochemistry was used to identify the 
Siaα2-6 and Siaα2-3 linkage and this lectin 
binding was re-examined after topical (surface) 
sialidase treatment. The presence of sialylated 
glycans in tissues was analysed using mass 
spectrometry. The presence of infection of 
human upper and lower respiratory tract tissue 
was tested after sialidase treatment with avian 
and human viruses.
3. There was a diffuse expression of Siaα2-6 
throughout the upper and lower respiratory 
tract. Siaα2-3 varied according to site with more 
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Introduction
The specificity of influenza for a particular host is 
mediated by the interaction of haemagglutinin 
(HA), a viral cell surface glycoprotein with host 
glycoconjugate receptors that contain terminal sialic 
acid (Sia) residues. The HA of influenza A strains 
that infect humans attaches preferentially to cells 
with Sia linked α2-6 residues to galactose, whereas 
avian strains preferentially bind Sia linked α2-3 
to galactose.1 As an example, the H5N1 viruses of 
the bird flu outbreak in Hong Kong in 1997 had an 
affinity for binding to avian α2-3 linked Sia.
 On the basis of binding by the lectin, Maackia 
amurensis agglutinin (MAA), Siaα2-3 (and thus 
H5N1 infection) appears to be restricted mainly 
to the human lower respiratory tract, whereas by 
Sambucus nigra agglutinin (SNA) binding, Siaα2-6 
linkages in both the upper and lower respiratory 
tract have been identified. This presumed inability 
of the H5N1 virus to establish infection in the 
upper respiratory tract has significant clinical and 
epidemiological implications. For example, H5N1 
transmission is unlikely to occur via droplets or 
ingestion, and will likely require aerosol transmission 
to reach the lower respiratory epithelium.
 Previously we used different isoforms of the 
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lectin MAA and demonstrated that MAA2 (which 
binds O-linked Siaα2-3) had limited binding in the 
upper respiratory tract, but there was widespread 
binding of MAA-I (which binds N-linked Siaα2-3) 
in the nasopharynx, adenoid and trachea of adults 
and children.2 We further went on to demonstrate 
that H5N1 viruses with only Siaα2-3 binding 
specificity could replicate in the upper respiratory 
tract of humans.3 There was widespread binding of 
MAA-I—the lectin that identifies Siaα2-3Gal—a 
binding preference of H5 viruses. This isoform of 
MAA did detect non-Sia termini such as sulphated 
galactose. 
 A new pharmaceutical agent—DAS181—
utilises the Aspergillus viscosus sialidase coupled 
together with an epithelial cell anchoring domain.4 
This fusion protein effectively degraded receptor Sia 
for both human and avian influenzas and potentially 
conferred protection against a broad range of 
influenza viruses. As MAA-I identified non-Sia 
residues, fresh tissues were also submitted for 
mass spectrometric analysis to determine residual 
glycoprotein profiles following DAS181 treatment. 
 If Sia are the sole receptors for influenza 
virus infection, then we proposed there would be 
an absence of influenza virus (IFV) infection as 
RESEARCH FUND FOR THE CONTROL OF INFECTIOUS DISEASES
N-linked Siaα2-3 glycans in the upper respiratory 
tract and more O-linked glycans in the lower 
respiratory tract. Sialidase treatment was able to 
remove both types of glycans. Unexpectedly, the 
effect of desialylation was not the same in all cell 
lines tested.
4. Both prophylactic as well as therapeutic sialidase 
treatment was able to prevent infection with 
avian and human influenza viruses. Sialidase 
therapy offers a potentially useful clinical option 
and is now in phase II clinical trial.
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determined by 50% tissue culture infectious dose 
(TCID50), enzyme-linked immunosorbent assay and 
immunohistochemistry following pre-incubation 
of normal upper respiratory tract tissues with 
neuraminidase (NA) and DAS181. Nonetheless, two 
reports have suggested that influenza virus infection 
may occur in the absence of NA, although these have 
been mainly confined to non-human or tumour cell 
lines. This warrants investigation of the alternate 
receptor hypothesis by exploring whether tissues 
can still be infected by influenza viruses despite NA 
or DAS181 treatment. 
Methods
This study was conducted from January 2009 to 
December 2010. Fresh biopsies were obtained from 
the normal nasopharynx and bronchus of individuals 
screened for nasopharyngeal carcinoma, and from 
healthy volunteers under a study approved by the 
Institutional Review Board of The University of Hong 
Kong and Hospital Authority (Hong Kong West). 
Lung tissue excised for pulmonary malignancy or 
other surgical procedures was also obtained. 
 Viruses used included A/HongKong/54/98 
(H1N1), A/Hong Kong/1174/99 (H3N2), A/Qu/HK/
G1/97( H9N2), A/Dk/HK/Y280/97 (H9N2), A/Hong 
Kong/213/03 (H5N1), A/Vietnam/3046/04 (H5N1).
 Infection was carried out using the viruses 
at a titre of 1×106 TCID50/ml, and ultraviolet light 
inactivated viruses as controls. Following incubation 
of the tissue fragments with the virus, the supernatant 
was removed and replaced with fresh medium. The 
tissue fragments of each biopsy were incubated at 
37ºC for 48 hours at which time they were fixed in 
10% neutral buffered formalin and processed for 
influenza nucleoprotein immunohistochemistry 
Lectin binding profiles
Sections were microwaved in 10 mM citrate buffer 
pH 6.0 at 95ºC for 15 minutes then blocked with 
3% H2O2 in TBS for 12 minutes and with avidin / 
biotin blocking kit (Vector Labs). They were then 
incubated with biotinylated MAA-I and MAA-II 
(Vector Labs) and horseradish peroxidase (HRP)-
labelled SNA and LFA (EY Labs) for 1 hour at 
room temperature, blocked with 1% bovine serum 
albumin for 10 minutes at room temperature, and 
then incubated with strep-ABC complex (Dako 
Cytomation, K-0377) diluted 1/100 for 30 minutes at 
room temperature. 
Neuraminidase and DAS181 treatment
Fresh and paraffin-embedded tissues were incubated 
with three different neuraminidases from Glyko 
(Glyko S – Siaα2,3 specific; Glyko N – Siaα2,3 and 
Siaα2,8 specific and Glyko A – Siaα2,3 and Siaα2,6 
specific) as well as DAS181 obtained from NexBio 
pharmaceuticals. Incubation was performed at 37ºC 
for 2 hours before influenza virus infection or lectin 
binding assessment. 
Mass spectrometric analysis
Frozen bronchus and lung tissue biopsies before 
and after DAS181 treatment were washed with PBS 
to remove any excreted mucus. Glycoproteins were 
solubilised from the tissues by homogenisation in a 
detergent extraction buffer. Extracted glycoproteins 
were reduced and carboxymethylated prior to 
tryptic protease digestion. N-linked glycans were 
enzymatically cleaved from the peptide backbone 
by digestion with peptide N-glycosidase F and 
subsequently purified on a Sep-Pak C18 reverse-
phase cartridge. O-glycans were chemically released 
from glycopeptides by reductive elimination. 
GC-MS linkage data were performed on glycan 
samples both before and after digestion with linkage 
specific sialidases (α2-3 specific from Streptococcus 
pneumoniae and α2-3, 6, 8,9 specific from 
Arthrobacter ureafaciens). MALDI-TOF MS profiles 
of permethylated glycans after sialidase digestion 
were recorded to assess the degree of desialylation.
Results
Sialidase treatment using Glyko A sialidase (which 
cleaves both α2-3 and α2-6 Sia) was able to remove 
binding of SNA and MAA to the epithelium, and this 
was more prominent in tissues from the bronchus 
and lung. 
 Using fresh bronchial and tracheal biopsies, the 
dosage of DAS181 necessary to lead to desialylation 
was determined. A concentration of 5 µg/cm2 was 
suitable to remove Sia from the surface epithelium, as 
shown by a decrease in SNA binding compared with 
the control. As DAS181 was not internalised there 
was no change in the intracellular Sia that remained 
in the goblet cells. Ten minutes exposure to DAS181 
was sufficient to lead to significant desialylation at 
10 µg/cm2, although by 30 minutes there was an equal 
level of desialylation at both 5 µg/cm2 and 10 µg/cm2. 
After a single treatment there was desialylation up 
to 48 hours with increased intracellular binding 
of SNA seen in bronchial epithelium associated 
with weak binding to the epithelium at 72 hours. 
This finding was in accord with an in vitro human 
airway epithelium finding; DAS181 at 5-10 µg/cm2 
was able to stop lectin binding indicating removal of 
extracellular Sia, and this effect lasted for 72 hours. 
 Accordingly, if Sia was the sole receptor for 
influenza, then removal of the Sia from glycans should 
diminish infection with influenza. Because H5N1 
is associated with a higher mortality than seasonal 
influenza, we initially focused on the prophylactic 
and therapeutic effect of DAS181 in H5N1 infection. 
After 2 hours incubation with DAS181, there was a 
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reduced binding of SNA and MAA and increased 
binding with PNA (which detects the exposed 
galactose). In a repeat experiment of the previously 
published mass spectrometric analysis, there was 
reduced sialylation after 2 hours incubation of lung 
tissues with DAS181. Infection experiments with 
H5N1 showed that control tissues had positive 
influenza nucleoprotein cells in the tissue sections 
indicating infection and this was reduced by a 
single dose of DAS181. Continuous exposure to 
DAS181 significantly abolished infection. When 
influenza M-gene analysis was performed, control 
H1N1, H3N2 and H5N1 tissues showed increased 
gene expression that was abolished after DAS181 
treatment.
 During the duration of the project, a new 
pandemic virus H1N1pdm emerged. We studied 
whether DAS181 would be able to abolish this 
infection. Pre-treatment with DAS181 prevented 
influenza virus replication as demonstrated by 
TCID50 and influenza M gene analysis.
Discussion
This project aimed to investigate interaction of the HA 
of different influenza viruses with the Sia present on 
the respiratory epithelium and how interfering with 
this interaction could affect influenza replication in 
the normal respiratory tract. We demonstrated that 
sialidase therapy was able to reduce lectin binding 
to epithelia from various sources (ie removal of both 
α2-3 and α2-6 linked glycans) and confirmed that 
different isoforms of the lectin Maackia amurensis 
should be used for detecting α2-3 type glycans. We 
then demonstrated that a single dose of DAS181 
was sufficient for desialylation and that the effect 
of desialylation could last for up to 3 days and that 
ciliated epithelial cells were the preferred target for 
desialyation in the bronchial epithelium. In addition, 
DAS181 treatment was able to effectively block 
H5N1 and other seasonal virus infection in ex vivo 
tissue.
 Overall, Sia was the main receptor for 
influenza, and removal of this Sia would be sufficient 
to abolish influenza virus infection. Nonetheless, 
how our findings correlate with findings in other 
studies in which influenza infection occurred in 
the presence of desialylation remained unclear. We 
therefore tested the effects of DAS181 on a wider 
range of influenza viruses (including H7N7 viruses, 
H1N1pdm, H3N2, H5N1 and H1N1 viruses) and 
used MDCK cells and CHO cells. As expected, 
DAS181 treatment markedly reduced infection in 
CHO cells with all viruses tested, but in MDCK cells 
despite DAS181 treatment there was still definite 
evidence of infection with most H5N1 viruses—A/
Vietnam/3046/04 (H5N1) and A/HongKong/54/98 
(H1N1). The two possibilities (which are not 
mutually exclusive) are (1) there are glycans present 
on MDCK cells that are not present on CHO cells 
and are resistant to sialidase treatment and (2) these 
two viruses have distinct binding profiles that allow 
binding to non-Sia glycans. 
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